Oct 9, 2026Weekly roundup

Pfizer registers real-world observational study of marstacimab in hemophilia A and B patients

Pfizer listed a new U.S. observational study tracking patient outcomes and treatment preferences for marstacimab in people with hemophilia A or B.

Pfizer's single registry update this week covers a new real-world evidence study for its hemophilia treatment marstacimab.

"MARVL-US" (NCT07859527) is a non-interventional observational study sponsored by Pfizer that is designed to find out what are the real-world experiences of people living with hemophilia A or B who start marstacimab in routine clinical practice.¹ The study is listed as not yet recruiting, with an estimated enrollment of 100 participants¹ and an estimated start date of 2026-10-05. Participants, who must be 6 years of age or older and the recipient of medical care in the United States¹, will be followed for about 1 year, during which they will complete up to six surveys.¹

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.

Sources

A Study to Learn About the Study Medicine (Called Marstacimab) in People With Hemophilia A or B ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Oct 7, 2026. Story written by readthrough.
Janus Kinase Inhibition in Granuloma Annulare ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Oct 9, 2026. Story written by readthrough.
A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Nov 6, 2026. Story written by readthrough.
A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Oct 30, 2026. Story written by readthrough.
A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC) ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Oct 8, 2026. Story written by readthrough.
A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Oct 9, 2026. Story written by readthrough.
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Nov 6, 2026. Story written by readthrough.
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Oct 9, 2026. Story written by readthrough.

About

abrocitinib cyclophosphamide darolutamide dupilumab enzalutamide irinotecan marstacimab-hncq palbociclib Pfizer Rsvpref temozolomide tilrekimig topotecan doxycycline hydroxychloroquine minocycline testosterone